Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.

Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP; TONES 3 Study Investigators.

Am J Respir Crit Care Med. 2019 Jun 1;199(11):1421-1431. doi: 10.1164/rccm.201806-1100OC.

PMID:
30521757
2.

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01089-18. doi: 10.1128/AAC.01089-18. Print 2018 Nov.

3.

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002).

Gotfried MH, Girod CE, Antin-Ozerkis D, Burgess T, Strombom I, Stauffer JL, Kirchgaessler KU, Padilla ML.

Pulm Ther. 2018 Jun;4(1):59-71. doi: 10.1007/s41030-018-0053-y. Epub 2018 Apr 5.

4.

Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Chugh R, Gupta M, Patel A, Chavan R, Yeole R, Friedland HD, Bhatia A.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00682-18. doi: 10.1128/AAC.00682-18. Print 2018 Aug.

5.

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.

Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, Bi S, Chavez-Eng CM, Zhang Z, Butterton JR.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01411-17. doi: 10.1128/AAC.01411-17. Print 2018 Mar.

6.

Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Chugh R, Gupta M, Yeole R, Patel A, Bhatia A.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02297-17. doi: 10.1128/AAC.02297-17. Print 2018 Mar.

7.

Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].

Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.

Respir Med. 2017 Aug;129:164. doi: 10.1016/j.rmed.2017.06.011. Epub 2017 Jun 30. No abstract available.

8.

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.

Gotfried MH, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, Manley A, Tanaka SK, Rodvold KA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01135-17. doi: 10.1128/AAC.01135-17. Print 2017 Sep.

9.

Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects.

Rodvold KA, Gotfried MH, Chugh R, Gupta M, Friedland HD, Bhatia A.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01096-17. doi: 10.1128/AAC.01096-17. Print 2017 Sep.

10.

A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.

Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.

Respir Med. 2016 Nov;120:16-24. doi: 10.1016/j.rmed.2016.09.012. Epub 2016 Sep 17. Erratum in: Respir Med. 2017 Aug;129:164.

11.

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, Rodvold KA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9. doi: 10.1128/AAC.01713-15. Epub 2015 Sep 8.

12.

A randomised trial of lung sealant versus medical therapy for advanced emphysema.

Come CE, Kramer MR, Dransfield MT, Abu-Hijleh M, Berkowitz D, Bezzi M, Bhatt SP, Boyd MB, Cases E, Chen AC, Cooper CB, Flandes J, Gildea T, Gotfried M, Hogarth DK, Kolandaivelu K, Leeds W, Liesching T, Marchetti N, Marquette C, Mularski RA, Pinto-Plata VM, Pritchett MA, Rafeq S, Rubio ER, Slebos DJ, Stratakos G, Sy A, Tsai LW, Wahidi M, Walsh J, Wells JM, Whitten PE, Yusen R, Zulueta JJ, Criner GJ, Washko GR.

Eur Respir J. 2015 Sep;46(3):651-62. doi: 10.1183/09031936.00205614. Epub 2015 Apr 2.

13.

A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.

Nechushtan H, Hamamreh Y, Nidal S, Gotfried M, Baron A, Shalev YI, Nisman B, Peretz T, Peylan-Ramu N.

Oncologist. 2015 Apr;20(4):366-7. doi: 10.1634/theoncologist.2014-0424. Epub 2015 Mar 16.

14.

A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis.

Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKevitt M, Montgomery AB, O'Riordan TG, Barker AF.

Chest. 2014 Aug;146(2):437-448. doi: 10.1378/chest.13-1891. Review. Erratum in: Chest. 2014 Nov;146(5):1422.

PMID:
24626872
15.

Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease.

Seth HD, Sultan S, Gotfried MH.

J Thorac Dis. 2013 Dec;5(6):806-14. doi: 10.3978/j.issn.2072-1439.2013.10.11. Review.

16.

Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures.

Bhattacharya I, Gotfried MH, Ji AJ, Saunders JP, Gourley I, Diehl A, Korth-Bradley JM.

J Clin Pharmacol. 2014 Jan;54(1):70-4. doi: 10.1002/jcph.201. Epub 2013 Oct 24.

PMID:
24155157
17.

The localized inflammatory response to bronchoscopic thermal vapor ablation.

Gompelmann D, Eberhardt R, Ernst A, Hopkins P, Egan J, Stanzel F, Valipour A, Wagner M, Witt C, Baker KM, Gotfried MH, Kesten S, Snell G, Herth FJ.

Respiration. 2013;86(4):324-31. doi: 10.1159/000354175. Epub 2013 Aug 23.

18.

Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.

Justo JA, Danziger LH, Gotfried MH.

Ther Adv Respir Dis. 2013 Oct;7(5):272-87. doi: 10.1177/1753465813487412. Epub 2013 May 20. Review.

PMID:
23690368
19.

Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.

Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B.

COPD. 2012 Dec;9(6):629-36. doi: 10.3109/15412555.2012.729623. Epub 2012 Sep 28.

PMID:
23020650
20.

Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2.

Davenport JM, Covington P, Gotfried M, Medlock M, Watanalumlerd P, McIntyre G, Turner L, Almenoff J.

Clin Pharmacol Drug Dev. 2012 Oct;1(4):121-30. doi: 10.1177/2160763X12454714.

PMID:
27121454
21.

Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema.

Herth FJ, Ernst A, Baker KM, Egan JJ, Gotfried MH, Hopkins P, Stanzel F, Valipour A, Wagner M, Witt C, Kesten S, Snell G.

Int J Chron Obstruct Pulmon Dis. 2012;7:397-405. doi: 10.2147/COPD.S31082. Epub 2012 Jul 18.

22.

Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects.

Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P.

Antimicrob Agents Chemother. 2012 Oct;56(10):5076-81. doi: 10.1128/AAC.00766-12. Epub 2012 Jul 16.

23.

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.

Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O.

J Antimicrob Chemother. 2012 Oct;67(10):2463-9. doi: 10.1093/jac/dks246. Epub 2012 Jul 6.

PMID:
22773741
24.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
25.

Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema.

Snell G, Herth FJ, Hopkins P, Baker KM, Witt C, Gotfried MH, Valipour A, Wagner M, Stanzel F, Egan JJ, Kesten S, Ernst A.

Eur Respir J. 2012 Jun;39(6):1326-33. doi: 10.1183/09031936.00092411. Epub 2011 Nov 10.

26.

Penetration of vancomycin into epithelial lining fluid in healthy volunteers.

Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA.

Antimicrob Agents Chemother. 2011 Dec;55(12):5507-11. doi: 10.1128/AAC.00712-11. Epub 2011 Sep 12.

27.

Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration.

Cassidy JP, Amin N, Marino M, Gotfried M, Meyer T, Sommerer K, Baughman RA.

Pharm Res. 2011 Sep;28(9):2157-64. doi: 10.1007/s11095-011-0443-4. Epub 2011 Apr 14.

PMID:
21491144
28.

Short-course fluoroquinolones in acute exacerbations of chronic bronchitis.

Gotfried MH, Grossman RF.

Expert Rev Respir Med. 2010 Oct;4(5):661-72. doi: 10.1586/ers.10.52. Review.

PMID:
20923343
29.

Fluoroquinolones in the management of community-acquired pneumonia.

Albertson TE, Dean NC, El Solh AA, Gotfried MH, Kaplan C, Niederman MS.

Int J Clin Pract. 2010 Feb;64(3):378-88. doi: 10.1111/j.1742-1241.2009.02239.x. Review.

PMID:
20456176
30.

Biologic lung volume reduction therapy for advanced homogeneous emphysema.

Refaely Y, Dransfield M, Kramer MR, Gotfried M, Leeds W, McLennan G, Tewari S, Krasna M, Criner GJ.

Eur Respir J. 2010 Jul;36(1):20-7. doi: 10.1183/09031936.00106009. Epub 2009 Nov 19.

31.

Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.

Jivcu C, Gotfried M.

Int J Chron Obstruct Pulmon Dis. 2009;4:291-300. Epub 2009 Aug 3. Review.

32.

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL.

Antimicrob Agents Chemother. 2009 Aug;53(8):3294-301. doi: 10.1128/AAC.00144-09. Epub 2009 May 18.

33.

Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results.

Criner GJ, Pinto-Plata V, Strange C, Dransfield M, Gotfried M, Leeds W, McLennan G, Refaely Y, Tewari S, Krasna M, Celli B.

Am J Respir Crit Care Med. 2009 May 1;179(9):791-8. doi: 10.1164/rccm.200810-1639OC. Epub 2009 Jan 29.

PMID:
19179484
34.

Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.

Lodise TP Jr, Gotfried M, Barriere S, Drusano GL.

Antimicrob Agents Chemother. 2008 Jul;52(7):2300-4. doi: 10.1128/AAC.01110-07. Epub 2008 Apr 21.

35.

Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL.

Antimicrob Agents Chemother. 2008 Jan;52(1):92-7. Epub 2007 Oct 8.

36.

Penetration of garenoxacin into lung tissues and bone in subjects undergoing lung biopsy or resection.

Krishna G, Gotfried MH, Rolston K, Wang Z.

Curr Med Res Opin. 2007 Aug;23(8):1841-7.

PMID:
17601364
37.

Role for 5-day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis.

Gotfried M, Busman TA, Norris S, Notario GF.

Curr Med Res Opin. 2007 Feb;23(2):459-66.

PMID:
17288699
38.
39.

Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ.

J Antimicrob Chemother. 2006 Dec;58(6):1221-9. Epub 2006 Sep 29.

PMID:
17012300
40.

Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide.

Bergeron C, Hauber HP, Gotfried M, Newman K, Dhanda R, Servi RJ, Ludwig MS, Hamid Q.

J Allergy Clin Immunol. 2005 Nov;116(5):983-9. Epub 2005 Oct 3.

PMID:
16275364
42.

Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.

Sprandel KA, Schriever CA, Pendland SL, Quinn JP, Gotfried MH, Hackett S, Graham MB, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2004 Dec;48(12):4597-605.

43.

Clarithromycin (Biaxin) extended-release tablet: a therapeutic review.

Gotfried MH.

Expert Rev Anti Infect Ther. 2003 Jun;1(1):9-20. Review.

PMID:
15482099
44.

Appropriate outpatient macrolide use in community-acquired pneumonia.

Gotfried MH.

J Am Acad Nurse Pract. 2004 Apr;16(4):146, 148, 150 passim. Review.

PMID:
15137473
45.

Macrolides for the treatment of chronic sinusitis, asthma, and COPD.

Gotfried MH.

Chest. 2004 Feb;125(2 Suppl):52S-60S; quiz 60S-61S. Review.

PMID:
14872001
46.

Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.

Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, Danziger LH.

Curr Ther Res Clin Exp. 2004 Jan;65(1):1-12. doi: 10.1016/S0011-393X(04)90000-8.

47.

Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects.

Gotfried MH, Danziger LH, Rodvold KA.

J Antimicrob Chemother. 2003 Sep;52(3):450-6. Epub 2003 Jul 29.

PMID:
12888589
48.

Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Rodvold KA, Danziger LH, Gotfried MH.

Antimicrob Agents Chemother. 2003 Aug;47(8):2450-7.

49.

Effect of HFA-flunisolide on peripheral lung inflammation in asthma.

Hauber HP, Gotfried M, Newman K, Danda R, Servi RJ, Christodoulopoulos P, Hamid Q.

J Allergy Clin Immunol. 2003 Jul;112(1):58-63.

PMID:
12847480
50.

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.

Gotfried M, Quinn TC, Gothelf S, Wikler MA, Webb CD, Nicholson SC.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):85-91.

PMID:
12376037

Supplemental Content

Loading ...
Support Center